- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Interventions
- Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 232
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
- Interventions
- Aspirin and/or Atorvastatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 17 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Romiplostim, Predniso(lo)ne
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Long Beach, California • Peoria, Illinois • Fredericksburg, Virginia
- Conditions
- Immune Thrombocytopenia (ITP)
- Interventions
- Placebo, Lusutrombopag
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 19
- States / cities
- Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- INCA000585
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atypical Hemolytic-Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 5
- States / cities
- Burlington, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Romiplostim
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 16
- States / cities
- Roseville, California • Atlanta, Georgia • Chicago, Illinois + 13 more
- Conditions
- Post Thrombotic Syndrome
- Interventions
- complex lymphedema therapy
- Other
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Immune Thrombocytopenia
- Interventions
- SKI-O-703, Placebo oral tablet
- Drug
- Lead sponsor
- Oscotec Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
- Conditions
- Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
- Interventions
- cyclophosphamide, filgrastim
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Deep Venous Thrombosis, Post-thrombotic Syndrome
- Interventions
- PET/CT
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Immune Thrombocytopenia
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Stanford, California • New York, New York
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- BIVV009 6.5 grams, BIVV009 7.5 grams
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- Eltrombopag olamine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Mezagitamab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 25
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Fostamatinib Disodium / R935788
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Cleveland, Ohio
- Conditions
- Deep Venous Thrombosis, Post Thrombotic Syndrome
- Interventions
- Catheter directed thrombolysis plus anticoagulation, Anticoagulation
- Combination Product · Drug
- Lead sponsor
- University of Toledo Health Science Campus
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Interventions
- Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 50 Years to 130 Years
- Enrollment
- 21,379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 250
- States / cities
- Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
- Conditions
- Immune Thrombocytopenic Purpura
- Interventions
- LGD-4665, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Manchester, Connecticut + 9 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- PF-06835375
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Immune Thrombotic Thrombocytopenia
- Interventions
- Caplacizumab
- Drug
- Lead sponsor
- US Thrombotic Microangiopathy Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Groveport, Ohio